Table 1.

Antiviral effects and cytotoxicity of S-PMEA 3 and S-PMPA 4 and reference compounds PMEA and PMPA, in CEM cells infected by 100 TCID₅₀ of HIV-1(III_a) or HIV-2(ROD), in H9 cells infected by 125 and 6250 TCID₅₀ of HIV-1-LAI and in activated PBMC infected by 100 TCID₅₀ of HIV-1-LAI.

Compounds	CEM			H9		PBMC	PBMC and H9
	EC50 (μM)a 100 TCID50 HIV-1(IIIB)	EC50 (μM)a 100 TCID50 HIV-2(ROD)	CC50 (μM)b	EC50 (μM)a 125 TCID50 HIV-1-LAI	EC50 (μM)a 6250 TCID50 HIV-1-LAI	EC50 (μM)a 100 TCID50 HIV-1-LAI	CC50 (μM)b
S-PMEA 3	16 ± 3.4	23 ± 19	233 ± 5.3	1.9 ± 1.8	17 ± 0.8	14 ± 10	>30
PMEA	5.5 ± 1.7	7.0 ± 4.3	85 ± 19	1.1 ± 0.7	7.9 ± 4.2	3.2 ± 2.1	>30
S-PMPA 4	14 ± 1.6	7.9 ± 3.0	>250	0.38 ± 0.10	9.7 ± 0.1	4.2 ± 3.9	>100
PMPA	4.1 ± 1.0	7.1 ± 5.7	>250	0.23 ± 0.05	8.3 ± 1.7	3.4 ± 3.2	>100

CEM: HumanT-Lymphoblastoid cells; H9: human lymphocyte cells; PMBC: Peripheral blood mononuclear cells.

^aEC₅₀ or concentration of drug that decreases the HIV replication by 50% (means of EC₅₀ from two blood donors).

^bCC₅₀ or concentration of drug that reduces the viable cell number by 50% (means of CC50 from two blood donors).